Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irofulven companion diagnostic - Allarity Therapeutics

Next Previous
Search
Drug Profile

Irofulven companion diagnostic - Allarity Therapeutics

Alternative Names: Irofulven Drug Response Predictor (DRP™) - Allarity Therapeutics; Oncology companion diagnostic

Latest Information Update: 08 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncology Venture
  • Developer Allarity Therapeutics; Oncology Venture A/S
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Liver cancer; Ovarian cancer

Most Recent Events

  • 08 Dec 2022 Irofulven companion diagnostic is still in phase II trials for Prostate cancer (Diagnosis) in Denmark (NCT03643107) (EudraCT2017-003549-72)
  • 08 Dec 2022 NDR batch #26: added ADS HE
  • 01 Aug 2022 Oncology Venture completes a phase II trial for Prostate cancer (Hormone refractory, Combination therapy, Second-line therapy or greater, Metastatic disease) in Denmark (IV) (NCT03643107) (EudraCT2017-003549-72)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top